case_images: PMC7091525_01
case_images: Red blood cell and white blood cell count recorded during Venetoclax monotherapy treatment from December 2018 to January 2020. The treatment initially began on November 28, 2018 at 100 mg and after one month was increased to 200 mg.
case_images: CRIHEM2020-9031067.001.jpg
case_images: PMC7091525_01_CRIHEM2020-9031067.001.jpg
case_images: fig1
case_images: The maximum cell counts since transfusion independence was achieved as follows: white blood cell count of 3.07 x 109/L, red blood cell count of 4.53, hemoglobin of 16 g/dL, and platelet count of 215,000 per microliter (Figures 1-3).
case_images: Hemoglobin recorded during Venetoclax monotherapy treatment from December 2018 to January 2020. The treatment initially began on November 28, 2018 at 100 mg and after one month was increased to 200 mg.
case_images: CRIHEM2020-9031067.002.jpg
case_images: PMC7091525_01_CRIHEM2020-9031067.002.jpg
case_images: fig2
case_images: The maximum cell counts since transfusion independence was achieved as follows: white blood cell count of 3.07 x 109/L, red blood cell count of 4.53, hemoglobin of 16 g/dL, and platelet count of 215,000 per microliter (Figures 1-3).
case_images: Platelet count recorded during Venetoclax monotherapy treatment from December 2018 to January 2020. The treatment initially began on November 28, 2018 at 100 mg and after one month was increased to 200 mg.
case_images: CRIHEM2020-9031067.003.jpg
case_images: PMC7091525_01_CRIHEM2020-9031067.003.jpg
case_images: fig3
case_images: The maximum cell counts since transfusion independence was achieved as follows: white blood cell count of 3.07 x 109/L, red blood cell count of 4.53, hemoglobin of 16 g/dL, and platelet count of 215,000 per microliter (Figures 1-3).